Research agenda developed for teen antipsychotic rx use

February 25, 2014
Research agenda developed for teen antipsychotic rx use
Prioritized research agendas have been developed for antipsychotic use among adolescents and young adults and for the management of ductal carcinoma in situ (DCIS), according to two reports published online Feb. 25 in the Annals of Internal Medicine.

(HealthDay)—Prioritized research agendas have been developed for antipsychotic use among adolescents and young adults and for the management of ductal carcinoma in situ (DCIS), according to two reports published online Feb. 25 in the Annals of Internal Medicine.

Matthew J. Crowley, M.D., from the Durham Veterans Affairs Medical Center in North Carolina, and colleagues describe the development of a prioritized research agenda relating to use among adolescents and with bipolar disorder. The existing literature was reviewed and a list of 23 potential evidence gaps identified. The stakeholders prioritized 10 high-priority evidence gaps, which related to three areas: comparative effectiveness of intervention strategies; the impact of medications of patient-centered outcomes; and the effect of patient characteristics on the effectiveness of antipsychotic medications.

In a second report, Jennifer M. Gierisch, Ph.D., M.P.H., from the Duke University School of Medicine in Durham, N.C., and colleagues describe the development of a prioritized research agenda relating to the different surveillance and management options for women with DCIS. The existing literature was reviewed to identify evidence gaps, and stakeholders ranked these using a forced-ranking prioritization method. The researchers identified the 10 highest-ranked evidence gaps, which related to incorporation of patient-centered outcomes into future research; improvement of risk prediction for ; evaluation of active surveillance as a strategy; and assessment of decision-making tools.

"Improvement of the ability of women given a DCIS diagnosis to make informed decisions about management options will be a critical need for the foreseeable future," Gierisch and colleagues write.

Explore further: Treatment priorities set in new national research effort

More information: Full Text - Crowley (subscription or payment may be required)
Editorial (subscription or payment may be required)
Full Text - Gierisch (subscription or payment may be required)

Related Stories

Treatment priorities set in new national research effort

February 24, 2014
Treatment regimens often evolve without strong scientific evidence of their benefits and drawbacks, particularly in comparison to other drugs or approaches.

Gaps exist in patient-centered quality of CRC care at VA

February 8, 2014
(HealthDay)—Patient-reported quality assessment measures reveal substantial gaps in patient-centered quality of colorectal cancer care, according to a study published online Feb 3 in the Journal of Clinical Oncology.

Terminology used to describe preinvasive breast cancer may affect patients' treatment preferences

August 26, 2013
When ductal carcinoma in situ (DCIS, a preinvasive malignancy of the breast) is described as a high-risk condition rather than cancer, more women report that they would opt for nonsurgical treatments, according to a research ...

USPSTF identifies high priority evidence gaps for older adults

November 20, 2013
(HealthDay)—The U.S. Preventive Services Task Force (USPSTF) has produced their third annual report for Congress identifying high-priority evidence gaps specifically relating to the care of older adults.

Fifty-five genes linked to a powerful tumor suppressor predict breast cancer survival

February 11, 2014
A panel of 55 genes, almost all of which are impacted by the loss of a particular protein, appears to predict if breast cancer will become invasive, leading to poorer survival, researchers at Georgetown Lombardi Comprehensive ...

Diagnostic and invasive procedures common in women with breast-conserving surgery

April 5, 2012
Women with ductal carcinoma in situ (DCIS) have high rates of diagnostic and invasive breast procedures after treatment with breast-conserving surgery (BCS) according to a study published April 5 in the Journal of the National ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.